Expertise in
15
conditions
Expertise in
15
conditions
Ssm Health Care Group
10101 Woodfield Ln, 
Saint Louis, MO 

Overview

William Ferguson is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Ferguson has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Ewing Sarcoma, Hepatoblastoma, Rhabdoid Tumor, Denys-Drash Syndrome (DDS), and Bone Marrow Aspiration.

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 57 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

SSM HEALTH CARE GROUP
10101 Woodfield Ln, Saint Louis, MO 63132

Additional Areas of Focus

Dr. Ferguson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


57 Clinical Trials

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
View 45 Less Clinical Trials
Similar Doctors
Experienced in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology
Experienced in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology

Ssm Health Care Group

1465 S Grand Blvd, 
Saint Louis, MO 
 (9.6 miles away)
Languages Spoken:
English

Jamie Truscott is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Truscott is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hepatoblastoma, Neuroblastoma, Hereditary Neuroblastoma, and Bone Marrow Transplant.

Pediatric Hematology Oncology
Pediatric Hematology Oncology
615 S New Ballas Rd, Suite 120, 
Saint Louis, MO 
 (3.3 miles away)
Languages Spoken:
English

Robin Hanson is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Hanson is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Hepatoblastoma, Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Pediatric Hematology Oncology
Pediatric Hematology Oncology

Washington University

1 Childrens Pl, 
Saint Louis, MO 
 (7.9 miles away)
Languages Spoken:
English

Michael Huang is a Pediatric Hematologist Oncology provider in Saint Louis, Missouri. Dr. Huang is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Traumatic Brain Injury, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Laminectomy, and Spinal Fusion.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferguson's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile